Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-903452 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-903452 (0.1 mg) or Placebo - A1 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (0.6 mg) or Placebo - A2 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (3.0 mg) or Placebo - A3 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (10 mg) or Placebo - A4 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (30 mg) or Placebo - A5 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (60 mg) or Placebo - A6 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (120 mg) or Placebo - A7 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (0.6 mg) or Placebo - B1 | EXPERIMENTAL | (Subjects with type 2 Diabetes Mellitus) |
| BMS-903452 (10 mg) or Placebo - B2 | EXPERIMENTAL | (Subjects with type 2 Diabetes Mellitus) |
| BMS-903452 (120 mg) or Placebo - B3 | EXPERIMENTAL | (Subjects with type 2 Diabetes Mellitus) |
| BMS-903452 (10 mg) or Placebo - A11 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (60 mg) or Placebo - A12 | EXPERIMENTAL | (Healthy Subjects) |
| Name | Type | Description |
|---|---|---|
| BMS-903452 | DRUG | Solution, Oral, 0.1 mg, once daily, 1 day |
| Placebo | DRUG | Solution, Oral, 0 mg, once daily, 1 day |
Inclusion Criteria: * Clinically healthy or Clinical diagnosis of Type 2 diabetes on a stable dose of metformin monotherapy Exclusion Criteria: * Type 1 Diabetes * History of significant heart disease * Prior bariatric surgery * Women of childbearing potential
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
BMS-903452 is an investigational small molecule being developed for the treatment of diabetes. It is a metabolic therapy that has been studied in healthy subjects and in patients with type 2 diabetes mellitus. The drug is currently in Phase 1 clinical development and is not yet approved.
BMS-903452 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and bioavailability of this investigational drug for diabetes.
BMS-903452 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, and relative bioavailability in healthy subjects and in patients with type 2 diabetes mellitus.
BMS-903452 has one completed Phase 1 clinical trial registered under NCT01240980. This study evaluated the safety of the drug in healthy subjects and assessed the relative bioavailability of its crystalline and amorphous forms, as well as its effects in subjects with type 2 diabetes mellitus. The trial enrolled 104 participants in the United States.
No alternative names for BMS-903452 have been disclosed. The drug is identified solely by its development code, BMS-903452, and is being investigated by Bristol-Myers Squibb for the treatment of diabetes.